Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 6/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 6/20 | 0.45 |
| ▸ | TTK | P33981 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.43 |
| ▸ | RELA | Q04206 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3084614 | 0.86 | KDM4E (0.54) | MEN1KMT2AKDM4ERAB9ANPC1 | |
| SCHEMBL6073484 | 0.86 | RAB9A (0.49) | MEN1KMT2AKDM4ERAB9ANPC1 | |
| SCHEMBL11249332 | 0.82 | KDM4E (0.37) | MEN1KMT2AKDM4ERAB9ANPC1 | |
| SCHEMBL760623 | 0.82 | MEN1 (0.46) | PIM1PIM2TTKMEN1KMT2A | |
| SCHEMBL16676801 | 0.82 | AHR (0.54) | PIM1PIM2TTKMEN1KMT2A | |
| SCHEMBL14620831 | 0.82 | SMN1; SMN2 (0.37) | MEN1KMT2AKDM4ERAB9ANPC1 | |
| SCHEMBL6833126 | 0.81 | SMN1; SMN2 (0.52) | KDM4ERAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL14625599 | 0.81 | SMN1; SMN2 (0.41) | MEN1KMT2AKDM4ERAB9ANPC1 | |
| SCHEMBL7563419 | 0.81 | SMN1; SMN2 (0.49) | KDM4ERAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL22493927 | 0.81 | SMN1; SMN2 (0.41) | MEN1KMT2AKDM4ERAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111757935-B | Bivalent nucleic acid ligands and uses thereof | 卡耐基梅隆大学 | 2025-02-21 | — | — | CN | disclosed |
| EP-3497103-B1 | PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS | PFIZER (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2016-10-20 | — | — | US | disclosed |
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2016-10-20 | — | — | US | disclosed |
| WO-2015084936-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-06-11 | — | — | WO | disclosed |
| EP-1363925-B8 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2007-04-25 | — | — | EP | disclosed |
| EP-1363925-B1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | disclosed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | disclosed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1363925-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002050091-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215495-A1 | Macrolide antibiotics | IL1R1, MRPL12, RPS21 | PIM1 1096/4885PIM2 1601/4885TTK 4768/4885 |
| US-20060211636-A1 | Macrolide Antibiotics | IL1R1, MRPL12, RPS21 | PIM1 1096/4885PIM2 1601/4885TTK 4768/4885 |
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | MAPK3, MAP3K3, MAP3K2 | PIM1 1217/4885PIM2 853/4885TTK 1071/4885 |
| US-20040077557-A1 | Macrolide antibiotics | MALT1, MRPL21, IL1R1 | PIM1 1012/4885PIM2 1408/4885TTK 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.